For a full list of our laboratory publications and citations, please use one of the following links:

Selected Research Articles

Lo MW, Amarilla AA, Lee JD, Albornoz EA, Modhiran N, Clark RJ, Ferro V, Chhabra M, Khromykh AA, Watterson D, Woodruff TM. (2022). SARS-CoV-2 triggers complement activation through interactions with heparan sulfate. Clinical and Translational Immunology. 11(8):e1413.

Li XX, Gorman DM, Lee JD, Clark RJ, Woodruff TM. (2022). Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages. Journal of Immunology. 208(1):133-142. 

Cui CS, Kumar V, Gorman DM, Clark RJ, Lee JD, Woodruff TM. (2021). In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy. ACS Pharmacology and Translational Science. 5(1):41-51.

Pandey S, Kumari P, Baidya M, Kise R, Cao Y, Dwivedi-Agnihotri H, Banerjee R, Li XX, Cui CS, Lee JD, Kawakami K, Maharana J, Ranjan A, Chaturvedi M, Jhingan GD, Laporte SA, Woodruff TM, Inoue A, Shukla AK. (2021) Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptors. Molecular CellS1097-2765(21)00741-3. 

McGill RB, Steyn FJ, Ngo ST, Thorpe KA, Heggie S, Ruitenberg MJ, Henderson RD, McCombe PA, Woodruff TM. (2020) Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. Brain Communications. 14;2(1):fcaa013.

Li XX, Lee JD, Massey NL, Guan C, Robertson AAB, Clark RJ, Woodruff TM. (2020) Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function. Biochemical Pharmacology180:114156.

Li XX, Clark RJ, Woodruff TM. (2020) C5aR2 Activation Broadly Modulates the Signaling and Function of Primary Human Macrophages. Journal of Immunology15;205(4):1102-1112. 

Deora V, Lee JD, Albornoz EA, McAlary L, Jagaraj CJ, Robertson AAB, Atkin JD, Cooper MA, Schroder K, Yerbury JJ, Gordon R, Woodruff TM. (2020) The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia. 68(2):407-421. 

Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, Robertson AAB, Butler MS, Rowe DB, O'Neill LA, Kanthasamy AG, Schroder K, Cooper MA, Woodruff TM. (2018). Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Science Translational Medicine. 10(465). pii: eaah4066.

Coulthard LG, Hawksworth OA, Li R, Balachandran A, Lee JD, Sepehrband F, Kurniawan N, Jeanes A, Simmons DG, Wolvetang E, Woodruff TM. (2017). Complement C5aR1 Signaling Promotes Polarization and Proliferation of Embryonic Neural Progenitor Cells through PKCζ. Journal of Neuroscience. 37(22):5395-5407.

Lee JD, Kumar V, Fung JN, Ruitenberg MJ, Noakes PG, Woodruff TM. (2017). Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. British Journal of Pharmacology. 174(8):689-699. 

Woodruff TM, Lee JD, Noakes PG. (2014). Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proc Natl Acad Sci USA. 111(1):E3-4.

Wu MC, Brennan FH, Lynch JP, Mantovani S, Phipps S, Wetsel RA, Ruitenberg MJ, Taylor SM, Woodruff TM. (2013). The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc Natl Acad Sci USA. 110(23):9439-44.

Selected Reviews

Parker SE, Bellingham MC, Woodruff TM. (2022). Complement drives circuit modulation in the adult brain. Progress in Neurobiology. 214: 102282.

Woodruff TM, Shukla AK. (2020) The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics. Trends in Immunology. 41(11):965-967. 

Lee JD, Coulthard LG, Woodruff TM. (2019) Complement dysregulation in the central nervous system during development and disease. Semin Immunol. 45:101340. 

Coulthard LG, Hawksworth OA, Woodruff TM. (2018). Complement: The Emerging Architect of the Developing Brain. Trends in Neuroscience. 41(6):373-384.

Coulthard LG, Woodruff TM. (2015). Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. Journal of Immunology. 194(8):3542-8.